[Function of B7/CD28 in anti-myeloma immunoreaction through activating T cells].
OBJECTIVE
To explore the role of B7/CD28 molecule in priming the anti-myeloma effect of T lymphocyte and the mechanism by which CD28 promoted the immunogenicity of myeloma cells.


METHODS
Human B7-1 gene was transducted into XG-s cells. CD28 agonist monoclonal antibody was primed. Primary allogeneic MLR, immunophenotypic analysis and quantitative measurement of IL-2 were performed.


RESULTS
XG cells were successfully transfected with B7-1 cDNA. The expressions of CD54, CD58, CD11a/CD18, CD40, CD40L, CD56, B7-2(CD86), HLA-I and HLA-II molecules were not affected by the transfection. The transduction of B7 gene dramatically increased the immunogenicity of tumor cells. In allo-MLR, the B7-1 expressing XG cell could more effectively mediate the activation, proliferation and IL-2 secretion of alloantigenic CD8+ T cells than XG cells did. Like B7-1 molecules, anti-CD28 agonistic McAb could induce the MLR of allo-T cell.


CONCLUSIONS
Human multiple myeloma cells failed to induce antitumor immunoreaction because of the weak expression of B7 molecules. The transfection of B7-1 or CD28 agonist antibody could stimulate and proliferate T lymphocytes and increase the immunogenicity of myeloma cells. CD28 agonist antibody might be promising for clinical application.
Guo
L
L
Department of Immunology, Suzhou Medical College, Suzhou 215007.
Zhang
X
X
Qiu
Y
Y
D000911:Antibodies, Monoclonal; D018122:B7-1 Antigen / Q000235:genetics*; D018106:CD28 Antigens / Q000235:genetics* / Q000276:immunology; D006801:Humans; D009101:Multiple Myeloma / Q000276:immunology* / Q000473:pathology; D013601:T-Lymphocytes / Q000276:immunology*; D014162:Transfection; D014407:Tumor Cells, Cultured
D000911:Antibodies, Monoclonal; D018122:B7-1 Antigen; D018106:CD28 Antigens